habcfoundationukMay 10, 20231 min readGreat news that Synapix Bio have secured £13.2m to fund clinical trials for H-ABC/Tubb4a!Oxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease. (synaptixbio.com)
Oxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease. (synaptixbio.com)
Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story
